Key Points
- Delcath CEO Gerard Michel purchased 11,500 shares at an average price of $8.53 on Nov. 11, raising his direct ownership to 330,834 shares (a 3.6% increase), as disclosed in an SEC Form 4.
- Shares jumped 5.3% to $9.07 on the day on volume of 248,583 (below its average of 651,427); the company has a market cap of $320.1M, a P/E of 181.7, and a 12‑month range of $8.33–$18.23.
- Analysts are mostly bullish—five Buys versus one Sell—giving a consensus rating of Moderate Buy with an average target of $22.40, though Weiss Ratings recently downgraded the stock to a sell.
Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) CEO Gerard Michel bought 11,500 shares of the business's stock in a transaction on Tuesday, November 11th. The stock was purchased at an average price of $8.53 per share, with a total value of $98,095.00. Following the completion of the transaction, the chief executive officer directly owned 330,834 shares of the company's stock, valued at $2,822,014.02. This trade represents a 3.60% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.
Delcath Systems Stock Up 5.3%
NASDAQ:DCTH traded up $0.46 during trading hours on Friday, reaching $9.07. 248,583 shares of the company's stock were exchanged, compared to its average volume of 651,427. The business's 50-day simple moving average is $10.55 and its two-hundred day simple moving average is $12.17. The company has a market capitalization of $320.12 million, a P/E ratio of 181.68 and a beta of 0.81. Delcath Systems, Inc. has a 12 month low of $8.33 and a 12 month high of $18.23.
Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported $0.02 EPS for the quarter, meeting analysts' consensus estimates of $0.02. The firm had revenue of $20.56 million for the quarter, compared to the consensus estimate of $23.22 million. Delcath Systems had a return on equity of 6.91% and a net margin of 3.18%. As a group, sell-side analysts anticipate that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Delcath Systems
A number of hedge funds and other institutional investors have recently bought and sold shares of DCTH. USA Financial Formulas bought a new stake in shares of Delcath Systems during the 2nd quarter valued at about $25,000. California State Teachers Retirement System bought a new stake in Delcath Systems during the 2nd quarter valued at approximately $26,000. Principal Financial Group Inc. boosted its stake in Delcath Systems by 2.1% during the first quarter. Principal Financial Group Inc. now owns 117,620 shares of the company's stock valued at $1,497,000 after buying an additional 2,437 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Delcath Systems in the 3rd quarter worth about $29,000. Finally, Tower Research Capital LLC TRC bought a new position in shares of Delcath Systems during the 2nd quarter valued at approximately $40,000. Hedge funds and other institutional investors own 61.12% of the company's stock.
Wall Street Analyst Weigh In
Several research firms have issued reports on DCTH. Canaccord Genuity Group restated a "buy" rating and issued a $21.00 price target on shares of Delcath Systems in a research report on Tuesday, October 21st. BTIG Research reaffirmed a "buy" rating and issued a $23.00 price target on shares of Delcath Systems in a research note on Tuesday, November 4th. HC Wainwright set a $30.00 price objective on Delcath Systems and gave the company a "buy" rating in a report on Monday, October 20th. Weiss Ratings downgraded Delcath Systems from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, November 7th. Finally, Stephens lowered their price objective on shares of Delcath Systems from $25.00 to $18.00 and set an "overweight" rating for the company in a research report on Wednesday, November 5th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $22.40.
Get Our Latest Stock Analysis on Delcath Systems
Delcath Systems Company Profile
(
Get Free Report)
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
